.png)
Did we pique your interest at ACOG?
Take the next step!
Thank you for your interest in VLISSE!
Keep up to date on the latest Vlisse news.
If you would like to receive notifications when we achieve critical milestones, please provide your contact information below. These will include alerts will include important press releases, FDA submissions and approvals, and other important news about our progress as we prepare to launch VLISSE.
Why Vlisse?
Vlisse™ is a prescription, drug-free medical device designed to treat vaginal yeast using patented controlled-cooling technology. Developed by a board-certified OB/GYN, Vlisse introduces a non-pharmaceutical approach that addresses infection and inflammation without the drugs, hormones, or chemicals commonly used in current treatments.
The Solution
Watch our ACOG video to learn more.
Background
Vulvovaginal candidiasis (VVC), caused primarily by Candida albicans, is treated with anti-fungal drugs, often with variable efficacy and relapses. New therapeutic strategies, including drug-free alternatives, are needed. Upon overgrowth or environmental triggers, C. albicans commensal yeast transitions into hyphae resulting in an aberrant immunopathologic neutrophil response that contributes to the characteristic signs and symptoms of vaginitis. The purpose of this study was to evaluate the efficacy of an intravaginal cooling device (Vlisse) in women with VVC to provide symptom relief via putative reversal of C. albicans hyphae to yeast, with additional proof of principle in an animal model.